Cantor Fitzgerald downgraded Arrowhead (NASDAQ:ARWR) from Buy to Hold in a statement released earlier today.
- Updated: November 30, 2016
Cantor Fitzgerald has downgraded Arrowhead (NASDAQ:ARWR) from Buy to Hold in a report released on 11/30/2016.
Previously on 2/10/2016, Jefferies & Co released a statement about Arrowhead (NASDAQ:ARWR) bumped down the target price from $7.00 to $4.00 that suggested an upside of 0.19%.
Showing a price of $4.39, Arrowhead (NASDAQ:ARWR) traded -1.57% lower on the day. With the last stock price close down -28.02% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same period. ARWR has recorded a 50-day average of $5.64 and a two hundred day average of $6.10. Trade Volume was down over the average, with 19,940 shares of ARWR changing hands under the typical 1,021,960
See Chart Below
Arrowhead has a 52 week low of $3.07 and a 52 week high of $8.22 The company’s market cap is currently $0.
A total of 3 equity analysts have released a ratings update on Arrowhead. zero analysts rating the company a strong buy, 2 firms rating the stock a buy, 2 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $8.92.
General Company Details For Arrowhead (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 for providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.